Evaluations of Targeted Delivery Systems for RNA Therapeutics
RNA therapeutics can target specific mRNAs with high specificity, making them advantageous for treating genetic diseases caused by known mutations. The lack of efficient, specific delivery strategies is a primary challenge and major hurdle to the development and widespread clinical application of RNA therapies. In recent years, significant progress has been made in both conjugate-based and carrier-based delivery systems. These advancements have been crucial in improving the safe, targeted delivery of oligonucleotide therapeutics to a range of tissues and organs.
To evaluate these systems, WuXi Biology has established a platform of in vitro and ex vivo assays to assess the cellular uptake and functional delivery of RNA therapeutics. At OTS 2025, our experts presented a poster demonstrating the platform’s capability to determine the binding and internalization of GalNAc conjugates, and to visualize and quantify cellular uptake, endosomal escape, and functional delivery of lipid nanoparticles.
Poster_OTS 2025_Targeted Delivery Systems for RNA Therapeutics
Related Content
Since the approval of the first siRNA drug in 2018, oligonucleotide therapeutics have rapidly emerged as a promising drug modality. ...
VIEW RESOURCEAntisense oligonucleotides (ASOs) are single-stranded, synthetic chains of DNA or RNA designed to bind to specific RNA sequences through complementary...
VIEW RESOURCE